Sherbrooke and Eastern
Type of Organization
Field of Activity
Milestone Pharmaceuticals Inc. (â€œMilestoneâ€�) is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestoneâ€™s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.
The Company has assembled a world-class scientific advisory board of key opinion leaders with significant cardiovascular expertise in cardiology, regulatory affairs, and drug development. Milestone has also assembled a panel of leading pharmaceutical drug development experts (â€œdrug huntersâ€�) who are current and former R&D executives from the pharmaceutical industry. The drug hunters identify and conceive NCE drug development projects based on clinically proven science to improve pharmacology profiles and/or reduce unwanted side effects through a focused medicinal chemistry approach. Milestone intends to develop these lead products into early clinical trials before licensing.